Continuous Release of Interleukin-2 from Liposomal IL-2 (Mixture of Interleukin-2 and Liposomes) after Subcutaneous Administration to Mice

Drug Development and Industrial Pharmacy

Volumn 29, Issue 10, 2003, Pages 1149-1153

  Kanaoka, Eri ^a   Takahashi, Kouji ^a   Yoshikawa, Takayoshi ^a   Jizomoto, Hiroaki ^a   Nishihara, Yoshitaka ^a   Hirano, Koichiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Adsorption; Liposome; Mean residence time (MRT); Recombinant interleukin 2 (IL 2); Subcutaneous

Indexed keywords

ANTINEOPLASTIC AGENT; IMUNACE; INTERLEUKIN 2; LIPOSOME; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG ADSORPTION; DRUG DISTRIBUTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN RESIDENCE TIME; MICROENCAPSULATION; MOUSE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED DRUG RELEASE;

ADSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LIPOSOMES; MALE; MICE;

EID: 0344629794     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120025872     Document Type: Article

References (22)

1. Kanaoka, E.; Takahashi, K.; Yoshikawa, T.; Jizomoto, H.; Nishihara, Y.; Uchida, N.; Maekawa, R.; Hirano, K. A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture). J. Control. Release 2002, 82, 183-187.
2. Gause, B.; Longo, D.L.; Janik, J.; Smith, I.I.; Curti, B.; Ochoa, A.; Kopp, W.C.; Anderson, P.; Urb, W.J. A phase I study of liposome-encapsulated IL-2. Proc. Am. Soc. Clin. Oncol. 1993, 12, 293.
3. Khanna, C.; Hasz, D.E.; Klausner, J.S.; Anderson, P.M. Aerosol delivery of interleukin-2 liposomes is nontoxic and biologically effective: canine studies. Clin. Cancer. Res. 1996, 2 (4), 721-734.
4. Konigsberg, P.J.; Godtel, R.; Kissel, T.; Richer, L.L. The development of IL-2 conjugated liposomes for therapeutic purposes. Biochim. Biophys. Acta 1998, 1370, 243-251.
5. Cabanes, A.; Even-Chen, S.; Zimberoff, J.; Barenholz, Y.; Kedar, E.; Gabison, A. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal IL-2. Clin. Cancer Res. 1999, 5 (3), 687-693.
6. Hirano, K.; Kanaoka, E.; Takahashi, K.; Yoshikawa, T.; Nishihara, Y.; Jizomoto, H. Biopharmaceutical studies on interleukin-2 simply mixed with liposomes. Prog. Drug Delivery System 1996, V, 113-116.
7. Kanaoka, E.; Takahashi, K.; Yoshikawa, T.; Jizomoto, H.; Nishihara, Y.; Hirano, K. A novel and simple type of liposome carrier for recombinant interleukin-2. J. Pharm. Pharmacol. 2001, 53 (3), 295-302.
8. Heys, S.D.; Gough, D.B.; Eremin, O. Immunotherapy with interleukin-2: recent developments. Exp. Opin. Invest. Drugs 1996, 5 (3), 269-288.
9. Semino, C.; Martini, L.; Queirolo, P.; Cangemi, G.; Costa, R.; Alloisio, A.: Ferlazzo, G.; Sertoli, M.R.; Real, U.M.; Ratto, G.B.; Melioli, G. Adoptive immunotherapy of advanced solid tumor: an eight year clinical experience. Anticancer Res. 1999, 19, 5645-5649.
10. Savas, B.; Arsla, G.; Gelen, T.; Karpuzoglu, G.; Ozkaynak, C. Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Res. 1999, 19, 4413-4420.
11. Schiphorst, P.P.; Chang, P.C.; Clar, N.; Schoemaker, R.C.; Osanto, S. Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancer. Ann. Oncol. 1999, 10 (11), 1381-1383.
12. Romanelli, F. Interleukin-2 for the management of HIV infection. J. Am. Pharm. Assoc. 1999, 39 (6), 867-868.
13. Bruton, J.K.; Koeller, J.M. Evaluation new drugs: recombinant interleukin-2. Pharmacotherapy 1994, 14 (6), 635-656.
14. Maxwell, A.C.A.; Durrant, L.G.; Scholefield, J.H. Immunotherapy for colorectal cancer. Am. J. Surg. 1999, 64, 344-348.
15. Den Otter, W.; Cadee, J.; Gavhumende, R.; De Groot, C.J.; Hennink, W.E.; Stewart, R. Effective cancer therapy with a single injection of interleukin-2 at the site of the tumor. Cancer Immunol. Immunother. 1999, 48 (7), 419-420.
16. Toh, H.C.; McAfee, S.L.; Sackstein, R.; Multani, P.; Cox, B.F.; Colby, C.; Spitzer, T.R. A phase II study of high dose (HD) cyclophsphamide+carboplatin and interleukin-2 (IL2) activated autologus peripheral blood stem cell transplantation (PBSCT) followed by subcutaneous (SC) IL2 therapy in metastatic breast carcinoma (MBC). Proc. Am. Soc. Clin. Oncol. 1999, 18 (35 Meet.), 47a.
17. Gonzalez-Barca, E.; Granena, A.; Fernandez-Sevilla, A.; Moreno, V.; Salar, A.; Rueda, F.; Garcia, J. Low-dose subcutaneous interleukin-2 in patients with minimal residual lymphoid neoplasm disease. Eur. J. Haematol. 1999, 62 (4), 231-238.
18. Queirolo, P.; Ponte, M.; Gipponi, M.; Cafiero, F.; Peressini, A.; Semino, C.; Pietra, G.; Lionetto, R.; Vecchio, S.; Ribizzi, I.; Melioli, G.; Sertoli, M.R. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon-alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group. Ann. Surg. Oncol. 1999, 6 (3), 272-278.
19. Kanaoka, E.; Nagata, S.; Hirano, K. The stabilization of aerosolized IFN-γ by liposomes. Int. J. Pharm. 1999, 188 (2), 165-172.
20. Terry, H. The therapeutic potential and problems of interleukin-2. Chem. Ind. 1993, 6, 663-665.
21. Lissoni, P.; Bolis, S.; Mandal'a, M.; Viviani, S.; Pogliani, E.; Barni, S. Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2. Int. J. Biol. Markers 1999, 14 (3), 167-171.
22. Dreau, D.; Bosserhoff, A.K.; White, R.L.; Buettner, R.; Holder, W.D. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy. Oncol. Res. 1999, 11 (1), 55-61.